Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Introducing the Finviz Matrix

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

TScan Therapeutics, Inc.

Contributing Author

Recent Articles by TScan Therapeutics, Inc.

Sep-02
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors TCRX -42.80% GlobeNewswire
Aug-12
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update TCRX GlobeNewswire
Jul-29
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies TCRX GlobeNewswire
Jun-24
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference TCRX GlobeNewswire
Jun-22
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation TCRX -5.97% GlobeNewswire
May-06
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update TCRX GlobeNewswire
Apr-27
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting TCRX GlobeNewswire
Apr-08
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference TCRX GlobeNewswire
Mar-04
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update TCRX GlobeNewswire
Feb-26
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 TCRX GlobeNewswire
Feb-25
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference TCRX +5.71% GlobeNewswire
Dec-06
TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition TCRX GlobeNewswire
Dec-03
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA Phase 1 Trial and Future Market Opportunities TCRX +7.12% TCRX +6.86% GlobeNewswire
Nov-12
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update TCRX GlobeNewswire
Nov-05
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference TCRX GlobeNewswire
Nov-03
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027 TCRX -36.08% GlobeNewswire
Sep-17
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025 TCRX -6.98% GlobeNewswire
Sep-03
TScan Therapeutics to Participate in Upcoming Investor Conferences TCRX +6.86% GlobeNewswire
Aug-12
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update TCRX GlobeNewswire
May-28
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference TCRX GlobeNewswire
May-06
TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update TCRX -9.33% GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)